An Open-label Clinical Study to Investigate Pharmacokinetics (PK) of Different Doses (0.125 mg, 0.25 mg, 0.5 mg) of Pramipexole Administered Once Daily Orally in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Pramipexole (Primary)
- Indications Restless legs syndrome
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 12 Sep 2014 New trial record